[Early Experience with MRI-Ultrasound Fusion-Guided Prostate Biopsy in Our Institution]

Autor: Naoto, Yoza, Ryuto, Nakazawa, Tomohiro, Nishi, Hikaru, Tsukada, Daisuke, Shirai, Hiroyuki, Adachi, Ryuji, Yamada, Kaori, Matsumura, Teppei, Iwata, Wataru, Usuba, Kouichirou, Aida, Nozomi, Hayakawa, Hideo, Sasaki, Eiji, Kikuchi
Rok vydání: 2022
Předmět:
Zdroj: Hinyokika kiyo. Acta urologica Japonica. 68(9)
ISSN: 0018-1994
Popis: A total of 100 patients were retrospectively analyzed with magnetic resonance imaging-ultrasonography (MRI-US) fusion biopsy(KOELIS, TRINITY®) at our institution between October 2019 and May 2020. The median patient age was 71 years, median prostate specific antigen (PSA) level was 7.4 ng/ml, and median PSA-density was 0.183 mg/ml. Sixty-one of the patients were positive for cancer ; 14 of them were positive by targeted biopsy only, 9 were positive by systematic biopsy only, and 38 were positive by both. Clinically significant prostate cancer (CPSC ; Gleason Score ≥3+4 and % core ≥50%) was detected by target biopsies in 46 patients and by systematic biopsies in 33 patients. The positive core detection rate for CSPC was 32.5% for targeted biopsies and 7.0% for systematic biopsies(P<0.0001), with a significantly higher rate for targeted biopsies. These results indicate that in MRI-US fusion biopsy, targeted biopsy has a higher detection rate for cancer and a significantly higher detection rate for clinically significant prostate cancer compared with systematic biopsy.
Databáze: OpenAIRE